Atara Biotherapeutics (ATRA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 75/100 (HIGH), 1.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 8.53% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
- Atara Biotherapeutics Announces Changes to Its Board of Directors
- FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
- Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
- Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
- Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
- Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
- Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Atara Biotherapeutics.
Full ATRA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.